|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Ohio Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing OhioLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Alkermes, Inc.
| | | Phone: | (937) 382-5642 | Year Established: | 1987 | Employees: | 81 | Ticker: | ALKS | Exchange: | NASDAQ | Main Contact: | Shane Cooke, President | | Other Contacts: | James Robinson, COO Craig Hopkinson, M.D., CMO & Senior VP, Clinical Development & Medical Affairs Srdjan (Serge) Stankovic, M.D., MSPH, Senior VP& CCO Peter Norman, VP, Government Affairs & Policy Richard Pops, Chairman & CEO Mark Stejbach, CCO Blar Jackson, Senior VP & Business Development Michael J. Landine, Senior VP, Corporate Development James M. Frates, Senior VP, CFO & Treasurer Elliot W. Ehrich, M.D., Senior VP, R&D Ian Brown, Senior VP, Finance Kathryn L. Biberstein, Executive VP & Chief Compliance Officer
| | Company Description | Alkermes is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in Ohio.
On May 9, 2011 Alkermes and Elan Corporation announced an agreement whereby Alkermes will merge with Elan Drug Technologies in a cash and stock transaction currently valued at approximately $960 million. Alkermes and EDT will be combined under a new holding company incorporated in Ireland named Alkermes plc. | |
|
|
|
|
|